Celltrion’s Remsima logs $17 mln sales in U.S.
SEOUL-- Celltrion Inc., a South Korean bio-pharmaceutical firm, said Thursday that the sales for its biosimilar, Remsima, topped US$17 million in the United States during the first quarter of this year.
The company said sales of the drug jumped more than 30 percent from a quarter earlier in the January-March period.
Remsima is an identical copy of Janssen Biotech, Inc.'s Remicade, and is effective in treating various diseases from rheumatoid arthritis to Crohn's disease. In the U.S. market, Remsima went on sale during the fourth quarter of last year under the name Inflectra by Pfizer Inc.
"The global sales of biosimilars made by Pfizer came to $105 million with the sale of Remsima accounting for $78 million," said a Celltrion official, who declined to be named.
Remsima was the second biosimilar ever to be approved by the U.S. Food and Drug Administration (FDA). Biosimilars are officially approved copycat medicines developed after patents for the original drugs expire.
Source: Yonhap News Agency